An In Vitro Monocyte Washout Model To Determine Molecular Differences Between Short And Long-Acting Inhaled Corticosteroids (ICS)

Amir Hakim; Malcolm Johnson; Peter J Barnes; Ian M. Adcock; Omar S. Usmani

doi:10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2956

An In Vitro Monocyte Washout Model To Determine Molecular Differences Between Short And Long-Acting Inhaled Corticosteroids (ICS) — Amir Hakim (2012) | RDL Network

An In Vitro Monocyte Washout Model To Determine Molecular Differences Between Short And Long-Acting Inhaled Corticosteroids (ICS)

Discussion(0)

Related publications

Clinical outcome of adding long-acting β-agonists to inhaled corticosteroids

Increasing Doses of Inhaled Corticosteroids Compared to Adding Long-Acting Inhaled β 2 -Agonists in Achieving Asthma Control

Scientific rationale for inhaled combination therapy with long-acting β<sub>2</sub>-agonists and corticosteroids

Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients

An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist.